A Senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism

Cancer Cell

Volumn 24, Issue 2, 2013, Pages 242-256

  Pribluda, Ariel ^a   Elyada, Ela ^a   Wiener, Zoltan ^b   Hamza, Haya ^a   Goldstein, RobertE ^a   Biton, Moshe ^a   Burstain, Ido ^a   Morgenstern, Yael ^a   Brachya, Guy ^a   Billauer, Hana ^a   Biton, Sharon ^a   Snir Alkalay, Irit ^a   Vucic, Domagoj ^c   Schlereth, Katharina ^d   Mernberger, Marco ^d   Stiewe, Thorsten ^d   Oren, Moshe ^e   Alitalo, Kari ^b   Pikarsky, Eli ^a   Ben Neriah, Yinon ^a  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF HELSINKI   (Finland)

^c GENENTECH INC   (United States)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P21; PROTEIN P53;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; COLORECTAL TUMOR; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; EPITHELIUM; EX VIVO STUDY; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION;

MUS;

EID: 84881526073     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.06.005     Document Type: Article

References (52)

1. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.
2. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
3. Bartek J., Hodny Z., Lukas J. Cytokine loops driving senescence. Nat. Cell Biol. 2008, 10:887-889.
4. Bartholomew J.N., Volonte D., Galbiati F. Caveolin-1 regulates the antagonistic pleiotropic properties of cellular senescence through a novel Mdm2/p53-mediated pathway. Cancer Res. 2009, 69:2878-2886.
5. Bartkova J., Horejsí Z., Koed K., Krämer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
6. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
7. Beazer-Barclay Y., Levy D.B., Moser A.R., Dove W.F., Hamilton S.R., Vogelstein B., Kinzler K.W. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996, 17:1757-1760.
8. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
9. Bhatia B., Multani A.S., Patrawala L., Chen X., Calhoun-Davis T., Zhou J., Schroeder L., Schneider-Broussard R., Shen J., Pathak S., et al. Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int. J. Cancer 2008, 122:1483-1495.
10. Burn J., Gerdes A.M., Macrae F., Mecklin J.P., Moeslein G., Olschwang S., Eccles D., Evans D.G., Maher E.R., Bertario L., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378:2081-2087. CAPP2 Investigators.
11. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302:649-658.
12. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
13. Cho S., Hwang E.S. Fluorescence-based detection and quantification of features of cellular senescence. Methods Cell Biol. 2011, 103:149-188.
14. Collado M., Serrano M. The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 2006, 6:472-476.
15. Collado M., Serrano M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 2010, 10:51-57.
16. Collado M., Blasco M.A., Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130:223-233.
17. Coppé J.P., Patil C.K., Rodier F., Sun Y., Muñoz D.P., Goldstein J., Nelson P.S., Desprez P.Y., Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008, 6:2853-2868.
18. Coppé J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010, 5:99-118.
19. Coppé J.P., Patil C.K., Rodier F., Krtolica A., Beauséjour C.M., Parrinello S., Hodgson J.G., Chin K., Desprez P.Y., Campisi J. A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS ONE 2010, 5:e9188.
20. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
21. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N.Engl. J. Med. 1986, 315:1650-1659.
22. Elyada E., Pribluda A., Goldstein R.E., Morgenstern Y., Brachya G., Cojocaru G., Snir-Alkalay I., Burstain I., Haffner-Krausz R., Jung S., et al. CKIα ablation highlights a critical role for p53 in invasiveness control. Nature 2011, 470:409-413.
23. Fijneman R.J., Bade L.K., Peham J.R., van de Wiel M.A., van Hinsbergh V.W., Meijer G.A., O'Sullivan M.G., Cormier R.T. Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways. Cell. Oncol. 2009, 31:345-356.
24. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
25. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
26. Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernández-Porras I., Cañamero M., Rodriguez-Justo M., Serrano M., Barbacid M. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19:728-739.
27. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
28. Ishikawa T.O., Herschman H.R. Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010, 31:729-736.
29. Kang T.W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., Hohmeyer A., Gereke M., Rudalska R., Potapova A., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
30. Kim B.H., Roh E., Lee H.Y., Lee I.J., Ahn B., Jung S.H., Lee H., Han S.B., Kim Y. Benzoxathiole derivative blocks lipopolysaccharide-induced nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene transcription through inactivating inhibitory kappaB kinase beta. Mol. Pharmacol. 2008, 73:1309-1318.
31. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. USA 2001, 98:12072-12077.
32. Kuilman T., Peeper D.S. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 2009, 9:81-94.
33. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
34. Leal J.F., Fominaya J., Cascón A., Guijarro M.V., Blanco-Aparicio C., Lleonart M., Castro M.E., Ramon Y Cajal S., Robledo M., Beach D.H., Carnero A. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene 2008, 27:1961-1970.
35. Liu D., Hornsby P.J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 2007, 67:3117-3126.
36. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
37. Meeker A.K., Hicks J.L., Iacobuzio-Donahue C.A., Montgomery E.A., Westra W.H., Chan T.Y., Ronnett B.M., De Marzo A.M. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 2004, 10:3317-3326.
38. Nardella C., Clohessy J.G., Alimonti A., Pandolfi P.P. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 2011, 11:503-511.
39. Petrova T.V., Nykänen A., Norrmén C., Ivanov K.I., Andersson L.C., Haglund C., Puolakkainen P., Wempe F., von Melchner H., Gradwohl G., et al. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell 2008, 13:407-419.
40. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., Fan A.C., Yang Q., Braunstein L., Crosby E., et al. CD4(+) Tcells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
41. Reimann M., Lee S., Loddenkemper C., Dörr J.R., Tabor V., Aichele P., Stein H., Dörken B., Jenuwein T., Schmitt C.A. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010, 17:262-272.
42. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., Meade T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
43. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., Clevers H. Single Lgr5 stem cells build crypt-villus structures invitro without a mesenchymal niche. Nature 2009, 459:262-265.
44. Sato T., Stange D.E., Ferrante M., Vries R.G., Van Es J.H., Van den Brink S., Van Houdt W.J., Pronk A., Van Gorp J., Siersema P.D., Clevers H. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011, 141:1762-1772.
45. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
46. Squires D.F. Neoplasia in a Coral?. Science 1965, 148:503-505.
47. Sutherland R., Buchegger F., Schreyer M., Vacca A., Mach J.P. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res. 1987, 47:1627-1633.
48. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
49. Varfolomeev E., Goncharov T., Maecker H., Zobel K., Kömüves L.G., Deshayes K., Vucic D. Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors. Sci. Signal. 2012, 5:ra22.
50. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression invivo. Nature 2007, 445:661-665.
51. Wang D., Dubois R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010, 29:781-788.
52. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.